Form 4: Verve Therapeutics Director Ourania Tatsis Granted 42,200 Stock Options

Verve Therapeutics, Inc. Director Ourania Tatsis was granted 42,200 stock options with an exercise price of $5.73, vesting over one year or prior to the next annual meeting, as part of the company's director compensation program.

Summary

• Ourania Tatsis, a Director of Verve Therapeutics, Inc. (VERV), was granted 42,200 stock options on June 5, 2025.
• The stock options have an exercise price of $5.73 per share.
• These options were issued under the company's 2021 Stock Incentive Plan as part of its director compensation program.
• The vesting commencement date is the grant date, and all shares underlying the option vest upon the earlier of the one-year anniversary of the vesting commencement date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The stock options have an expiration date of June 4, 2035.
• Following this transaction, Ourania Tatsis directly beneficially owns 42,200 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard practice for aligning management and director interests with shareholders. It reflects routine corporate governance and compensation practices and is generally viewed positively as it incentivizes long-term performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term value creation.
• This transaction is part of a pre-existing and disclosed director compensation program, indicating structured corporate governance.

Future Outlook

N/A This Form 4 filing primarily reports an insider transaction related to director compensation and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program.

Industry Context

This is a routine insider transaction (Form 4) reporting a director's equity compensation. Such grants are common practice in the biotechnology and pharmaceutical industries to align director incentives with long-term shareholder value, especially for companies like Verve Therapeutics which are typically in the R&D phase and rely on equity-based compensation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector.
• The specific number of options (42,200) and exercise price ($5.73) would need to be compared against peer companies of similar market capitalization and stage of development (e.g., other gene-editing or rare disease focused biotechs) to assess if it's within typical ranges for director compensation packages. Without specific peer data, it's difficult to provide a detailed comparative assessment, but the mechanism itself is standard.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ourania Tatsis, a director, constitutes a related party transaction. However, it is disclosed as part of a pre-approved and standard director compensation program (2021 Stock Incentive Plan), which is common practice for public companies.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is mentioned in this filing.

Next Steps

• The granted options will vest upon the earlier of the one-year anniversary of the grant date (June 5, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continued service as a director.

Key Dates

Keywords

Verve Therapeutics, VERV, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Ourania Tatsis, Biotechnology